One-year findings of the LUMINOUS study, the first global, large-scale observational study on ranibizumab in routine clinical practice, showed good disease control, with maintained or increased vision and a complication rate comparable to that of clinical trial settings. Full Story »
The study is gradually recruiting a total of 30,000 patients with age-related macular degeneration, diabetic macular edema and retinal vein occlusion over a period of 3 years, with a possible extension to 4 years and an additional 10,000 patients. The United Kingdom, Canada, Australia, China and Russia are involved, and other countries are expected to join the project. Treatment-naïve and previously treated eyes are included and analyzed separately.